arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Silence Therapeutics plc

SLN

$11.94 ▲ +0.21 (+1.75%) at close

5 Visible periods

26 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Silence Therapeutics plc faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.7B

Dividend Yield —

Revenue Growth -98.7% ↘

Op. Margin None

ROIC -146.2% ↘

FCF / Share $-0.44 ↗

Trailing P/E —

Price / Book 27.2x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

5-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$559.00K

↓ -98.7% —

Net Income Profit after all expenses

$-88.61M

↓ -95.6% —

Operating Margin Operating profit as % of sales

-146.4%

↑ +28.1% —

FCF / Share Free cash flow per share

$-0.44

↑ +10.1% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↑

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Revenue Growth YoY (%)	-98.7% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1334%)	36.7% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+359%)	46.1% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+477%)	—	—
EPS Growth YoY (%)	-90.9% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	32.7% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	5.8% Fair Fair Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	-95.6% Weak ↓ Weak Declining Year-over-year change in net income	16.4% Good Good Year-over-year change in net income	-7.7% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	10.1% Fair ↑ Fair Improving Year-over-year change in free cash flow	-9.9% Weak Weak Year-over-year change in free cash flow	24.9% Good Good Year-over-year change in free cash flow	—	—
Revenue CAGR 3Y (%)	-70.4% Weak Weak Compound annual revenue growth over 3 years	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Operating Margin (%) (%)	—	-146.4% Weak ↑ Weak Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1076%)	-203.5% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1456%)	-281.9% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1979%)	—
Effective Tax Rate (%) (%)	-0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-1.9% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-1.8% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	-1.4% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—
Profit Margin (%) (%)	—	-104.7% Weak ↑ Weak Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-973%)	-171.4% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1528%)	-232.4% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2037%)	—
FCF Margin (%) (%)	—	-156.9% Weak ↑ Weak Improving Free cash flow as a percentage of revenue Optimal: > 10%	-156.5% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	-264.2% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—
FCF / Net Income (x)	0.70x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.50x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	0.91x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	1.14x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Return on Invested Capital (%)	-146.2% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-48.1% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-298.0% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-227.3% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-69.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-31.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	-53.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	-142.2% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1048%)	-33.8% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-325%)	-246.6% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1744%)	-184.9% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1333%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Net Debt (USD)	$-11.28M	$-121.33M	$-68.79M	—	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Revenue per Share (USD)	$0.00	$0.31	$0.28	$0.22	—
Basic EPS, GAAP (USD)	$-0.63	$-0.33	$-0.49	$-0.52	—
Free Cash Flow per Share (USD)	$-0.44	$-0.49	$-0.44	$-0.59	—
Book Value per Share (USD)	$0.44	$0.95	$0.19	$0.25	—
Tangible Book Value per Share (USD)	$0.36	$0.88	$0.10	$0.16	—
Basic Weighted Avg Shares (shares)	141.69M	138.75M	111.28M	96.58M	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Working Capital (USD)	$105.05M	$170.54M	$80.81M	—	—
Total Equity (USD)	$62.30M	$134.02M	$21.99M	$27.22M	$12.37M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Sales/Revenue/Turnover (USD)	$559.00K	$43.26M	$31.64M	$21.66M	—
Depreciation Expense (USD)	$312.00K	$336.00K	$369.00K	$379.00K	—
Net Income, GAAP (USD)	$-88.61M	$-45.31M	$-54.23M	$-50.33M	—
Operating Cash Flow (USD)	$-62.27M	$-67.64M	$-49.46M	$-57.04M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 5 years · 9 quarters

Silence Therapeutics plc

Analytical Summary

5-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare SLN with peers